AUSTIN, Texas, Dec. 29, 2017 -- Bravatek Solutions, Inc. (OTCPink:BVTK) (“Bravatek” or the “Company”) announces that it executed its highly anticipated Joint Venture (“JV”) announced today with DarkPulse Technologies, Inc. (“DPT”). The Company released an 8-K on this subject a few days ago. In addition, the Company announces that it has started invoicing this month against the $21.4 M PO it received recently and reported in an 8-K and press release.
Mr. Dennis O’Leary, DPT’s Chairman and CEO commented: “We are very excited to consummate this JV with Bravatek. We were so impressed with their knowledge of the markets—but are truly amazed regarding all the other resources they have brought to bear. In a short time—they have assisted us with technical resources and opened up sales channels due to Tom [Cellucci]’s laser physics background, as well as an authority on public-private partnerships for Critical Infrastructure/Key Resources (CI/KR). Together we are significantly stronger to address the multitude of security and health-monitoring needs in the majority of the US’ 18 CI/ KR markets--allowing placement of our patented technology in a multitude of existing and new applications.
Dr. Thomas A. Cellucci, Chairman and CEO of BVTK commented: “We have been laser-focussed on assisting Dennis [O’Leary] and his team on building a powerhouse of capabilities to meet CI/KR application demand. We have had early success and we believe continued success in providing much need protection to the critical infrastructure –supported by virtually all US politicians, as well as citizenry.”
About Bravatek Solutions, Inc.
Bravatek Solutions, Inc. is a high technology security solutions portfolio provider that assists corporate entities, governments and individuals protect their organizations against both physical and cyber-attacks through its offering of the most technically-advanced, cost-effective and reliable software, tools and systems.
For more information, visit www.bravatek.com
Safe Harbor Statement
This press release contains certain “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Bravatek Solutions, Inc.
1.866.490.8590


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Instagram Outage Disrupts Thousands of U.S. Users
Washington Post Publisher Will Lewis Steps Down After Layoffs
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



